
Yuehe Lin. Photo Courtesy of PNNL
A precise and non-toxic treatment that targets lung cancer cells at the nanoscale is able to effectively kill the cells even at a low dose.
Researchers from Washington State University and the Department of Energy’s Pacific Northwest National Laboratory (PNNL) used tiny tubes made from organic molecules called peptoids to deliver cancer-killing drugs in a targeted manner. The research, led by Yuehe Lin, professor in WSU’s School of Mechanical and Materials Engineering, and Chun-Long Chen, a senior research scientist at PNNL and a joint faculty fellow at the University of Washington, was published as the cover story in the prestigious journal Small.
The biologically-inspired nanotubes, which are about a hundred thousand times thinner than a human hair, were rolled up from membrane-like nanosheets. The drug molecules, fluorescent dyes and cancer-targeting molecules were precisely placed within the nanotubes, enabling them to track the efficiency of drug delivery into the cancer cells.
The new technology allows the two drugs – one for chemotherapy and the other for a less-invasive photodynamic therapy treatment – to be delivered directly to the cancer cells. Photodynamic therapy uses a chemical that, when exposed to light, releases reactive oxygen species (ROS) that kill cancer cells. The researchers’ dual-drug approach enabled the use of a lower dose of the cancer drugs than using a single drug, leading to effective killing of cancer cells with low toxicity.
“By precisely engineering these nanotubes with fluorescent dyes and cancer targeting molecules, scientists can clearly locate tumor cells and track how the drug regimen is performing,” said Lin. “We can also track how nanotubes enter and deliver the drugs inside the cancer cell.”
The team tested the nanotubes on lung cancer cells and found that they delivered the chemotherapy drug doxorubicin directly into the fast-dividing cancer cells, resulting in highly efficient cancer killing while using less chemotherapy drugs.
“This is a promising approach for precision targeting with little damage to healthy surrounding cells,” said Lin.
While other nanomaterials, such as carbon nanotubes, have been used to deliver and track cancer-killing drugs, researchers have found that they are toxic to the body. Furthermore, they didn’t do well at precisely recognizing molecules.
“By using these peptoids, we were able to develop highly programmable nanotubes and a biocompatible delivery mechanism,” said Chen. “We also harnessed the high stability of peptoid and its well-controlled packing to develop nanotubes that are highly stable.”
“Due to their unique structure, these nanotubes can be easily assembled for use in cancer therapy and stay in the body longer for treatment,” said Lin.
The team is now looking for collaboration and funding opportunities with pharmaceutical companies to extend the research into animal and clinical studies.
Learn more: New drug-delivery technology promises efficient, targeted cancer treatment
The Latest on: Lung cancer
[google_news title=”” keyword=”lung cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Lung cancer
- UPDATE 3-Amgen's late-stage data for lung cancer drug 'not adequate' - FDA staffon October 4, 2023 at 2:11 am
Amgen's drug was granted accelerated approval by the U.S. FDA in 2021 for advanced lung cancer patients with KRAS mutations whose disease has worsened after treatment with chemotherapy or other medicines. The U.S. health regulator grants the so-called ...
- Machine Learning Can Better ID Who Needs Lung Cancer Screeningon October 3, 2023 at 6:30 pm
TUESDAY, Oct. 3, 2023 (HealthDay News) -- A machine learning model that uses only data on age, smoking duration, and pack-years can predict lung cancer risk and identify who needs lung cancer screening with better performance than currently used methods ...
- Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concernson October 3, 2023 at 12:49 pm
The FDA released briefing documents ahead of Oncologic Drugs Advisory Committee meeting scheduled for October 5 to review Amgen Inc's (NASDAQ:
- Takeda announces voluntary withdrawal of lung cancer therapyon October 2, 2023 at 1:13 pm
Takeda Pharmaceutical said on Monday it would be working with the U.S. health regulator towards a voluntary withdrawal of its lung cancer therapy in the country, after it failed to meet the main goal in a late-stage study.
- Lung Disease Newson September 30, 2023 at 5:01 pm
Sep. 21, 2023 — Small cell lung cancer accounts for about 15 percent of all diagnosed lung cancers and is still associated with a high mortality rate. SCLC tumours often develop resistance to ...
- J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drugon September 28, 2023 at 9:23 am
Sept 28 (Reuters) - Johnson & Johnson (JNJ.N) said its cancer drug combination increased the time patients with a type of non small-cell lung cancer live without the disease worsening compared to ...
- Worrying signs of lung cancer in arm and shoulder you need to get checked outon September 28, 2023 at 3:43 am
Lung cancers often spread more quickly than other forms of cancer, with cancer cells spreading through blood into lungs and other parts of the body. This means that this type of cancer is often ...
- Lung Cancer Newson September 21, 2023 at 5:00 pm
Sep. 21, 2023 — Small cell lung cancer accounts for about 15 percent of all diagnosed lung cancers and is still associated with a high mortality rate. SCLC tumours often develop resistance to ...
via Bing News